A clear guide to GLP-1 receptor agonists, the class of medications behind Ozempic, Wegovy, and more. Learn what they are, how they work in the body, and how the different options compare for diabetes and weight loss.
GLP-1 Agonists
GLP-1 medications like semaglutide and tirzepatide are widely used for weight loss, but doctors are raising serious concerns about their use in people with eating disorders. This article explains the specific risks, what screening should look like, and the questions you should ask before starting treatment.
Eli Lilly's next-generation obesity drug has shown weight loss results approaching those seen with bariatric surgery in a late-stage clinical trial. Here's what that breakthrough means for people currently on GLP-1 medications and those weighing their options for 2026 and beyond.
Many people on GLP-1 medications report a surprising side effect: the constant mental preoccupation with food simply quiets down. This article explains what food noise is, why GLP-1 drugs seem to reduce it, and what that could mean for your weight loss journey.
Generic semaglutide has arrived on Canadian pharmacy shelves, raising questions about safety, effectiveness, and cost. Here's what patients need to know about how generic Ozempic compares to the brand-name version, and what this development could mean for access and pricing across North America.
A growing number of people taking GLP-1 medications like semaglutide and tirzepatide report subtle shifts in mood, motivation, and personality. Some call it feeling "flat" or less like themselves. We break down what the research actually shows, why it might happen, and what to discuss with your doctor.
A Maryland board has voted to cap how much state and local governments will spend on Ozempic, signaling a growing trend of public employers pushing back on GLP-1 costs. If you're on semaglutide through employer coverage or considering it, here's what you need to know about how these decisions could affect your access and out-of-pocket expenses.
Clinical trials show dramatic variation in weight loss results among people taking GLP-1 medications like Wegovy and Mounjaro. Some patients lose 25% or more of their body weight while others see far more modest results. Understanding what drives these differences can help you set realistic expectations and take steps to improve your own outcomes.
Novo Nordisk reported slower-than-expected growth in Wegovy oral tablet prescriptions, raising questions for patients weighing pill vs. injection options. This article breaks down what's driving the slowdown, what the data actually means, and how to decide which format fits your treatment goals.
